Promising new cocktail aims to tame multiple myeloma with fewer side effects

NCT ID NCT02412228

Completed Disease control Sponsor: John L. Reagan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of three drugs—ixazomib, cyclophosphamide, and dexamethasone—as a first treatment for multiple myeloma. The goal was to see if this mix works better and causes fewer nerve problems than standard options. Twelve newly diagnosed patients took part, receiving the drugs in cycles over about 1.5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ixazomib (a targeted cancer drug), cyclophosphamide (a chemotherapy drug), and dexamethasone (a steroid)
What this could lead to: If successful, this combination could offer a more effective and less toxic first-line treatment option for multiple myeloma, potentially improving outcomes and quality of life.
What could go wrong: This is a small, early-phase trial with only 12 participants, so results may not apply broadly. The drugs still carry risks of side effects, and the regimen may not prove superior to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Hospital of Rhode Island

Pawtucket, Rhode Island, 02860, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
The Miriam Hospital

Providence, Rhode Island, 02906, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.